ArticleJournal of neuro-oncology2018
TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Prognostic significance of brain invasion in meningiomas: systematic review and meta-analysis.Brain tumor pathology · 2021Pooled it
- Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.Neurosurgical review · 2020Pooled it
- The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.Journal of neuro-oncology · 2019Pooled it
- Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).Neuro-oncology · 2022Trial
- Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [European journal of nuclear medicine and molecular imaging · 2021Trial
- The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis.The Lancet. Oncology · 2025Article
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- Evaluation of prognostic biomarkers in meningiomas and their clinical implications in settings with limited resources.Neuro-oncology practice · 2024Article
- A comprehensive correlation of the KI-67 proliferation index to patient´s, imaging and tumor features and its value in predicting long-term course of patients with newly diagnosed intracranial meningiomas.Neurosurgical review · 2024Article
- Perifocal edema is a risk factor for preoperative seizures in patients with meningioma WHO grade 2 and 3.Acta neurochirurgica · 2024Article
- Novel Postoperative Serum Biomarkers in Atypical Meningiomas: A Multicenter Study.Neurosurgery · 2023Article
- Review
- Introduction: Ongoing clinical challenges in the management of meningiomas and future directions.Neuro-oncology advances · 2023Article
- Shunt dependency in supratentorial intraventricular tumors depends on the extent of tumor resection.Acta neurochirurgica · 2023Article
- Article
- Mutational signature of extracranial meningioma metastases and their respective primary tumors.Acta neuropathologica communications · 2023Article
- Genomic Landscape of Meningiomas.Advances in experimental medicine and biology · 2023Article
- Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers.BMC medical genomics · 2022Article
- Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.Cancer science · 2022Article
- Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?Journal of neuro-oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTranscriptional activating mutations in the promoter region of the telomerase reverse transcriptase (TERT) gene occur at high frequency in various types of solid tumors and have also been reported for meningiomas. Especially for atypical and anaplastic meningiomas, the prognostic relevance of TERT promoter mutation is yet unclear. The present study aimed to analyze the frequency of TERT promoter mutation and define its long-term prognostic significance beyond clinical and histological factors in a cohort of meningiomas WHO grade II and III.
methodsPatients undergoing surgical resection of aggressive meningiomas were included. Analysis for C228T and C250T mutation in the TERT promoter region was performed using PCR method. Patients were stratified into two groups (TERT mutated vs. TERT wild type). Univariate analysis was conducted using molecular and histological factors.
results87 patients with atypical (N = 72) and anaplastic meningiomas (N = 15) were included in the study. TERT promoter region was found to be mutated in 4 WHO grade II and 2 WHO grade III meningiomas. TERT promoter mutation was associated with shorter progression free survival than TERT wild type meningiomas (median PFS 12.5 vs. 26 months, p = .004). In the univariate analysis, TERT promoter mutation had a strong prognostic value on overall survival (p = .009) and progression free survival.
conclusionsPresence of TERT promoter mutation is associated with shorter progression free survival and overall survival in meningiomas WHO grade II and III. In these tumors, TERT promoter mutation should be considered as a clinically relevant prognostic factor to identify high risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.